Stay updated with breaking news from Practice Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaMinjuvi
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous15.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology...
National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022
Through research in regenerative medicine, advancement has been shown to improve and treat diseases ..